Overview

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Status:
RECRUITING

Trial end date:
2031-03-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.

Phase:

PHASE2

Details

Lead Sponsor:

Peking University First Hospital

Collaborators:

Beijing Biote Pharmaceutical Co.,Ltd
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Treatments:

Leuprolide